– UK, Edinburgh – Monks Investment Trust PLC (LON: MNKS) today announced the appointment of Dr. Dina Chaya (Ph.D.) to its Board as a non-executive Director, effective on 30 November 2022.
“I am delighted that Dr. Chaya has agreed to bring her healthcare expertise and investment experience to our Board,” said Board Chairman, Karl Sternberg.
About Dr. Dina Chaya
Dr. Chaya is an Adviser to Omega Funds and a Partner with NeoMed Management. She currently serves on the board of Anjarium Biosciences, Imago BioSciences, Oxular, and Spruce Biosciences. Dr. Chaya has been investing in the private equity and venture capital healthcare industry since 2001, previously at 3i in London and Index Ventures in Geneva.
She is a CFA charter holder and has a Ph.D. degree in Molecular and Cellular Biology of Development from Paris VI University. She carried out postdoctoral research at Brown University, Providence, and at the Fox Chase Cancer Centre, Philadelphia.
For more information: https://www.bailliegifford.com/en/uk/individual-investors/funds/monks-investment-trust/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.